ImmunoPrecise Antibodies (IPA) Expected to Announce Earnings on Monday

Key Points

• ImmunoPrecise Antibodies will announce its Q1 2026 results on September 15, with analysts predicting earnings of ($0.04) per share and revenue of $5.90 million.
• The company reported negative earnings in its last results, missing consensus estimates, with a net margin of -122.10%.
• Shares of ImmunoPrecise Antibodies have seen an increase, and analyst ratings have shifted from a "sell" to a "hold," with a target price of $4.00.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Monday, September 15th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.04) per share and revenue of $5.90 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earningreport for the latest details on the call scheduled for Monday, September 15, 2025 at 10:30 AM ET.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The business had revenue of $5.06 million during the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative return on equity of 40.62% and a negative net margin of 122.10%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunoPrecise Antibodies Stock Performance

Shares of ImmunoPrecise Antibodies stock traded up $0.17 on Wednesday, hitting $2.10. 1,970,657 shares of the company's stock were exchanged, compared to its average volume of 1,833,589. ImmunoPrecise Antibodies has a 1 year low of $0.27 and a 1 year high of $3.25. The company has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $1.05. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.85 and a current ratio of 2.08. The stock has a market capitalization of $96.68 million, a PE ratio of -3.08 and a beta of 0.53.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded ImmunoPrecise Antibodies from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, ImmunoPrecise Antibodies currently has an average rating of "Buy" and a consensus target price of $4.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. XTX Topco Ltd boosted its holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) by 394.4% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 91,382 shares of the company's stock after buying an additional 72,897 shares during the period. XTX Topco Ltd owned 0.20% of ImmunoPrecise Antibodies worth $97,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.70% of the company's stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.